New drug combo shows promise against aggressive thyroid cancer

NCT ID NCT05696548

First seen Apr 25, 2026 · Last updated May 12, 2026 · Updated 5 times

Summary

This study tests whether combining two drugs, nivolumab and lenvatinib, can shrink tumors in people with anaplastic thyroid cancer that cannot be removed by surgery. About 51 adults with this rare and fast-growing cancer will receive the treatment. The main goals are to check safety and see how many patients have their tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aichi Cancer Center

    Nagoya, Aichi-ken, 464-8681, Japan

  • Hokkaido University Hospital

    Hokkaido, Hokkaido, 060-8648, Japan

  • Hyogo Cancer Center

    Akashi, Hyōgo, 673-8558, Japan

  • Kobe University Hospital

    Kobe, Hyōgo, 650-0017, Japan

  • National Cancer Center Hospital

    Tokyo, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, 277-8577, Japan

  • Nippon Medical School Hospital

    Tokyo, Tokyo, 113-8603, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Osaka, 545-8586, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, 980-8574, Japan

  • Yokohama City University Hospital

    Yokohama, Kanagawa, 236-0004, Japan

Conditions

Explore the condition pages connected to this study.